Clinical Trials Logo

Recurrent Hairy Cell Leukemia clinical trials

View clinical trials related to Recurrent Hairy Cell Leukemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06311227 Recruiting - Clinical trials for Recurrent Hairy Cell Leukemia

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Start date: February 14, 2025
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.

NCT ID: NCT00412594 Recruiting - Hairy Cell Leukemia Clinical Trials

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Start date: June 10, 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.